These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24513220)

  • 1. Formation of protein sub-visible particles during vacuum degassing of etanercept solutions.
    Wang H; Zheng HJ; Wang Z; Bai H; Carpenter JF; Chen S; Fang WJ
    Int J Biol Macromol; 2014 May; 66():151-7. PubMed ID: 24513220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of protein sub-visible particles during powder grinding of a monoclonal antibody.
    Qian C; Wang G; Wang X; Barnard J; Gao JQ; Bao W; Wang H; Li F; Ingle RG; Fang WJ
    Eur J Pharm Biopharm; 2020 Apr; 149():1-11. PubMed ID: 32006605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Grinding-Induced Subvisible Particles and Free Radicals in a Freeze-Dried Monoclonal Antibody Formulation.
    Jing ZY; Huo GL; Sun MF; Shen BB; Fang WJ
    Pharm Res; 2022 Feb; 39(2):399-410. PubMed ID: 35083639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Freeze-Dried Biopharmaceutical Formulations are Surprisingly Less Stable than Liquid Formulations during Dropping.
    Fang WJ; Pang MJ; Liu JW; Wang X; Wang H; Sun MF
    Pharm Res; 2022 Apr; 39(4):795-803. PubMed ID: 35314998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effects of Excipients on Freeze-dried Monoclonal Antibody Formulation Degradation and Sub-Visible Particle Formation during Shaking.
    Jin MJ; Ge XZ; Huang Q; Liu JW; Ingle RG; Gao D; Fang WJ
    Pharm Res; 2024 Feb; 41(2):321-334. PubMed ID: 38291165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein Sub-Visible Particle and Free Radical formation of a Freeze-Dried Monoclonal Antibody Formulation During Dropping.
    Fang WJ; Liu JW; Zheng HJ; Shen BB; Wang X; Kong Y; Jing ZY; Gao JQ
    J Pharm Sci; 2021 Apr; 110(4):1625-1634. PubMed ID: 33049261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of analytical methods to detect instability of etanercept during thermal stress testing.
    Maarschalkerweerd Av; Wolbink GJ; Stapel SO; Jiskoot W; Hawe A
    Eur J Pharm Biopharm; 2011 Jun; 78(2):213-21. PubMed ID: 21272639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive evaluation of etanercept stability in various concentrations with biophysical assessment.
    Kim NA; Lim DG; Lim JY; Kim KH; Jeong SH
    Int J Pharm; 2014 Jan; 460(1-2):108-18. PubMed ID: 24269208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of etanercept stability as exposed to various sugars with biophysical assessment.
    Lim DG; Kim NA; Lim JY; Kim KH; Hada S; Jeong SH
    Int J Pharm; 2014 Dec; 476(1-2):50-9. PubMed ID: 25269011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
    Schüle S; Friess W; Bechtold-Peters K; Garidel P
    Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis.
    Zölls S; Gregoritza M; Tantipolphan R; Wiggenhorn M; Winter G; Friess W; Hawe A
    J Pharm Sci; 2013 May; 102(5):1434-46. PubMed ID: 23463514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
    Nishi H; Mathäs R; Fürst R; Winter G
    J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
    Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying.
    Jovanović N; Bouchard A; Hofland GW; Witkamp GJ; Crommelin DJ; Jiskoot W
    Eur J Pharm Sci; 2006 Mar; 27(4):336-45. PubMed ID: 16338123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Secondary Package on Freeze-Dried Biopharmaceutical Formulation Stability During Dropping.
    Fang WJ; Liu JW; Barnard J; Wang H; Qian YC; Xu J
    J Pharm Sci; 2021 Aug; 110(8):2916-2924. PubMed ID: 33940028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thermal ink-jet spray freeze-drying for preparation of excipient-free salbutamol sulphate for inhalation.
    Mueannoom W; Srisongphan A; Taylor KM; Hauschild S; Gaisford S
    Eur J Pharm Biopharm; 2012 Jan; 80(1):149-55. PubMed ID: 22001519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
    Werk T; Volkin DB; Mahler HC
    Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods.
    Hawe A; Schaubhut F; Geidobler R; Wiggenhorn M; Friess W; Rast M; de Muynck C; Winter G
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1084-7. PubMed ID: 23454051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins III: collapse during storage at elevated temperatures.
    Schersch K; Betz O; Garidel P; Muehlau S; Bassarab S; Winter G
    Eur J Pharm Biopharm; 2013 Oct; 85(2):240-52. PubMed ID: 23727369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of freeze-drying parameters and formulation composition on IgG stability during drying.
    Heljo VP; Harju H; Hatanpää T; Yohannes G; Juppo AM
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):752-5. PubMed ID: 23623795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.